Vironexis Biotherapeutics
Latest round
- Seed
Last raised
- Oct 2022
Total raised
- $26M
Investors
- 4
About Vironexis Biotherapeutics
Founded in 2021, Vironexis Biotherapeutics specializes in AAV-delivered therapies aimed at revolutionizing cancer treatment. The founder, Timothy Cripe, previously established other ventures that underscore his expertise in biotech.Vironexis Biotherapeutics specializes in pioneering AAV-delivered T-cell immuno-gene therapies designed to transform cancer treatment. The core offering is their AAV Gene Therapy Platform, TransJoin™, which allows for the delivery of engineered transgenes to T cells through a one-time infusion, eliminating the need for pre-treatment and custom manufacturing. Their therapies primarily serve patients with blood-based cancers and aim to prevent solid tumor metastasis.Vironexis Biotherapeutics generates revenue through strategic partnerships and collaborations with healthcare institutions, pharmaceutical companies, and research organizations. Their revenue model focuses on B2B transactions, involving licensing agreements, milestone payments, and revenue-sharing arrangements, particularly through their flagship product, the TransJoin™ AAV Gene Therapy, which targets tumors and aims for a sustained immune response. The company is focusing on expanding its product pipeline for innovative cancer treatments and aims to enter additional markets in Europe and Asia by 2025, in response to the growing demand for effective cancer therapies.
Who invested in Vironexis Biotherapeutics
4 investors across 1 round
See all investors in Vironexis Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Oct 1, 2022
Amount
$26M
Investors
Questions about Vironexis Biotherapeutics
Who invested in Vironexis Biotherapeutics?
Vironexis Biotherapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vironexis Biotherapeutics raised?
Vironexis Biotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Vironexis Biotherapeutics last raise money?
Vironexis Biotherapeutics's most recent round on record is a Seed, in Oct 2022.
What does Vironexis Biotherapeutics do?
Founded in 2021, Vironexis Biotherapeutics specializes in AAV-delivered therapies aimed at revolutionizing cancer treatment.
Where is Vironexis Biotherapeutics headquartered?
Vironexis Biotherapeutics is headquartered in US.
Which VCs invest in companies like Vironexis Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Vironexis Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Vironexis Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.